FDA approves Actemra to treat rare form of juvenile arthritis

Posted by (author unknown) on Friday Apr 15, 2011 Under Uncategorized

The U.S. Food and Drug Administration today approved Actemra (tocilizumab), given alone or in combination with methotrexate, for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in children ages 2 years and older.

Be Sociable, Share!

Comments are closed.